FY2026 EPS Estimates for Harrow Boosted by Cantor Fitzgerald

Harrow, Inc. (NASDAQ:HROW) – Equities researchers at Cantor Fitzgerald boosted their FY2026 earnings per share (EPS) estimates for shares of Harrow in a report issued on Wednesday, August 13th. Cantor Fitzgerald analyst S. Seedhouse now expects that the company will post earnings per share of $2.39 for the year, up from their previous forecast of $2.12. Cantor Fitzgerald has a “Overweight” rating and a $76.00 price objective on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share.

Several other equities research analysts also recently issued reports on HROW. BTIG Research reaffirmed a “buy” rating and set a $63.00 price target (up previously from $62.00) on shares of Harrow in a report on Thursday. William Blair initiated coverage on Harrow in a report on Tuesday, June 10th. They set an “outperform” rating for the company. Finally, HC Wainwright lifted their target price on Harrow from $60.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Harrow has a consensus rating of “Buy” and an average target price of $64.67.

Harrow Trading Down 3.0%

Shares of Harrow stock opened at $38.82 on Thursday. The business has a fifty day simple moving average of $33.18 and a two-hundred day simple moving average of $28.91. Harrow has a 1 year low of $20.85 and a 1 year high of $59.23. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of -155.28 and a beta of 0.41. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.62 and a quick ratio of 0.85.

Harrow (NASDAQ:HROW) last announced its quarterly earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.23. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. The business had revenue of $63.74 million during the quarter, compared to the consensus estimate of $64.23 million.

Institutional Investors Weigh In On Harrow

A number of hedge funds and other institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new position in Harrow in the fourth quarter valued at about $25,000. Quarry LP acquired a new position in Harrow in the first quarter valued at about $32,000. Raymond James Financial Inc. acquired a new position in Harrow in the second quarter valued at about $48,000. Tower Research Capital LLC TRC raised its stake in Harrow by 769.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company’s stock valued at $55,000 after purchasing an additional 1,462 shares in the last quarter. Finally, Aquatic Capital Management LLC acquired a new position in Harrow in the fourth quarter valued at about $78,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.